Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Surrozen Operating, Inc. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners and 2 distinct art units. This indicates that while the company's technology is concentrated in a few technical areas, it is being reviewed by several different individuals.
YU, DELPHINUS DOU YI is the busiest examiner for the company, currently overseeing 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, each examiner is responsible for exactly 1 case. This distribution provides the company with multiple points of contact within the patent office for its 3 pending office actions.
The use of 2 distinct art units suggests that the company's Biotechnology & Pharmaceuticals filings fall into two primary technical classifications. Managing 3 pending office actions across 3 distinct examiners requires a coordinated strategy to ensure consistency. This profile shows an active and moderately diverse prosecution pipeline within the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18350589 | ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE | WEIDNER, ADAM M | — |
| 17438303 | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18597679 | TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF | YU, DELPHINUS DOU YI | — | §112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18350589 | ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE | WEIDNER, ADAM M | 1675 | §112 | Non-Final OA | — | Pending | Jul 11, 2023 |
| 17438303 | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS | LI, RUIXIANG | 1674 | §112 | Non-Final OA | — | Pending | Sep 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial